Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 4
Submit an article Journal homepage
428
Views
1
CrossRef citations to date
0
Altmetric
Letter

Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

Imane AbouyahyaDepartment of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands
,
Canan AlhanDepartment of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands
,
Theresia M. WestersDepartment of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands
,
Peter A. te BoekhorstDepartment of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
,
Mies C. Kappers-KlunneDepartment of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
,
Jules L. CoenenDepartment of Internal Medicine, Isala Klinieken, The Netherlands
,
Fenna H. HeyningDepartment of Hematology, Medical Center Haaglanden, The Hague, The Netherlands
,
Gerwin A. HulsDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Joost T. de WolfDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Alex L. ImholzDepartment of Medical Oncology, Deventer Hospital, Deventer, The Netherlands
,
Harry R. KoeneDepartment of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Gerda VethDepartment of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Evert-Jan F. M. de KruijfDepartment of Hematology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
,
Petra MuusDepartment of Hematology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
,
Erwin V. PlankenDepartment of Internal Medicine, Diaconessenhuis Leiden, Leiden, The Netherlands
,
Christine M. SegerenDepartment of Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands
,
Wies L. VasmelDepartment of Internal Medicine, Sint Lucas Andreas Hospital, Amsterdam, The Netherlands
,
Ankie M. van der VeldenDepartment of Internal Medicine, Tergooi Hospitals Blaricum, Blaricum, The Netherlands
,
Gerjo A. VeldersDepartment of Internal Medicine, Hospital Gelderse Vallei, Ede, The Netherlands
,
Jan Koedam Celgene B.V., Utrecht, The Netherlands
,
Gert J. OssenkoppeleDepartment of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands
&
Arjan A. van de LoosdrechtDepartment of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The NetherlandsCorrespondence[email protected]
 show all
Pages 874-877 | Received 17 Apr 2012, Accepted 05 Sep 2012, Published online: 28 Sep 2012

References

  • Schechter J, Galili N, Raza A. MDS: refining existing therapy through improved biologic insights. Blood Rev 2012;26:73–80.
  • Pellagatti A, Jädersten M, Forsblom AM, . Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104:11406–11411.
  • List A, Kurtin S, Roe DJ, . Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–557.
  • List A, Dewald G, Bennett J, . Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456–1465.
  • Le Bras F, Sebert M, Kelaidi C, . Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion–the GFM experience. Leuk Res 2011;35:1444–1448.
  • Fenaux P, Giagounidis A, Selleslag D, . A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765–3776.
  • Mitelman F, editor. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel: Karger; 1995.
  • Cheson BD, Greenberg PL, Bennett JM, . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
  • Common toxicity criteria, version 3.0. Bethesda, MD: National Cancer Institute.
  • Adès L, Le Bras F, Sebert M, . Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica 2012;97:213–219.
  • Sugimoto Y, Sekeres MA, Makishima H, . Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 2012;5:4.
  • Sibon D, Cannas G, Baracco F, . Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 2012;156:619–625.
  • Raza A, Reeves JA, Feldman EJ, . Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86–93.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.